IRCT2014070218314N1已完成2 期
Clinical Trials of new bivalent snake antivenom immunoglobulins (IgG) for the treatment of envenoming by medically important vipers in Sindh (Phase II study)
Department of health, Governement of Sindh0 个研究点目标入组 12 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years(—)
- 性别
- All
入选标准
- •Inclusion Criteris: Patient envenomed by Saw Scaled Viper (Echis carinatus Sochureki/ lundi) and Russell’s viper (Daboia Russelii/Daman/Koriala); Adult male or female (non-pregnant) above 18 years.Reached hospital within few hours (within 0-7 hours) of snake bite. However the late reaching patients will be treated according to provincial protocol of snakebite management without inclusion in the study; Snake specie is confirmed by identification of dead snake or the clinical observation of incoagulable blood, or when a description of snake is associated with symptoms and signs consistent with systemic envenoming by viper species such as incoagulable blood, spontaneous systemic bleeding, intravascular hemolysis, (pink plasma, anemia, hemoglobinuria), acute renal failure or oliguria; 20WBCT shows incoagulable blood; Patients show no early (anaphylactic) reaction within 10-30 minutes (itching, urticaria, fever, nausea, vomiting, tachycardia, hypotension, bronchospasm) on administration of 0.3ml of test ASV as initial dose; Patient or his/her legally acceptable representative able to understand the informed consent and enter into the study with their free will by signing the same.
排除标准
- •Not willing to accept newly produced ASV as the core remedy; Debilitated patients and those with other chronic or complicating medical conditions, any neuropathy, renal impairment, liver diseases, diabetes mellitus, Hypertension and any CV disease; Subject with known hypersensitivity to horse (equine) or sheep (ovine) serum in the past (for example after treatment with equine anti-tetanus serum, equine anti-rabies serum or equine or ovine anti-venom) and those with a strong history of atopic diseases (especially severe asthma); Patients showing reaction to initial dose of test ASV; Patients with severe condition, acute renal failure, anuria, generalized rhabdomyolysis evident with myoglobinuria and haemoglobinuria; Pregnant women and patients under 18 years of age; not bitten by any medically important vipers of Sindh.
研究者
相似试验
已完成
2 期
Comparison of Two Dose Regimens of Snake Antivenom for the Treatment of Snake Bites Envenoming in NepalSnake BiteNCT01284855CTU250
已完成
4 期
Redback Spider AntiVenom Evaluation (RAVE) StudyRedback spider envenomingOther - Pain managementACTRN12605000146695Geoff Isbister400
已完成
不适用
Study on infusion rate of snake antivenom therapySnakebites requiring antivenom administrationSLCTR/2007/005IRQUE Project206
尚未招募
Unknown
Adjustment of antisnake venom dose in snake bite poisoningCTRI/2024/05/067306Indian Council of Medical Research
尚未招募
4 期
Clinical study of snake antipruritic pills in the treatment of chronic spontaneous urticariaChronic spontaneous urticariaITMCTR2200005651guangdong Provincial Hospital of Chinese Medicine
